REFERENCES
- Schaumberg DA, Nichols JJ, Papas EB et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011; 52: 1994–2005.
- Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology 1993; 100: 347–351.
- Nelson JD, Shimazaki J, Benitez‐del‐castillo JM et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2011; 52: 1930–1937.
- Goto E, Endo K, Suzuki A et al. Tear evaporation dynamics in normal subjects and subjects with obstructive meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2003; 44: 533–539.
- Shimazaki J, Sakata M, Tsubota K. Ocular surface changes and discomfort in patients with meibomian gland dysfunction. Arch Ophthalmol 1995; 113: 1266–1270.
- Mcculley JP, Shine WE. Meibomian gland function and the tear lipid layer. Ocul Surf 2003; 1: 97–106.
- Geerling G, Tauber J, Baudouin C et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050–2064.
- Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs 2015; 75: 1177–1185.
- Benitez‐del‐castillo JM. How to promote and preserve eyelid health. Clin Ophthalmol 2012; 6: 1689–1698.
- Knop E, Knop N, Millar T et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 2011; 52: 1938–1978.
- Nichols KK, Foulks GN, Bron AJ et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52: 1922–1929.
- Lee H, Min K, Kim EK et al. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol 2012; 154: 949–957 e1.
- Souchier M, Joffre C, Gregoire S et al. Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment. Br J Ophthalmol 2008; 92: 819–822.
- Shine WE, Mcculley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003; 76: 417–420.
- Foulks GN, Borchman D, Yappert M et al. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea 2010; 29: 781–788.
- Perry HD, Doshi‐carnevale S, Donnenfeld ED et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006; 25: 171–175.
- Arita R, Suehiro J, Haraguchi T et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol 2013; 97: 725–729.
- Lee H, Chung B, Kim KS et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial. Am J Ophthalmol 2014; 158: 1172–1183 e1.
- Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc 1980; 51: 243–251.
- Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment of meibomian gland dysfunction. Adv Exp Med Biol 1994; 350: 293–298.
- King‐smith PE, Hinel EA, Nichols JJ. Application of a novel interferometric method to investigate the relation between lipid layer thickness and tear film thinning. Invest Ophthalmol Vis Sci 2010; 51: 2418–2423.
- Finis D, Pischel N, Schrader S et al. Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for Meibomian gland dysfunction. Cornea 2013; 32: 1549–1553.
- Arita R, Itoh K, Inoue K et al. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology 2009; 116: 379–384.
- Pflugfelder SC, Tseng SC, Sanabria O et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear‐film disorders known to cause ocular irritation. Cornea 1998; 17: 38–56.
- Tomlinson A, Bron AJ, Korb DR et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 2011; 52: 2006–2049.
- Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid changes. Eye (Lond) 1991; 5: 395–411.
- Schiffman RM, Christianson MD, Jacobsen G et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118: 615–621.
- Korb DR, Blackie CA. Meibomian gland therapeutic expression: quantifying the applied pressure and the limitation of resulting pain. Eye Contact Lens 2011; 37: 298–301.
- Kunnen CM, Brown SH, Lazon de la jara P et al. Influence of Meibomian Gland Expression Methods on Human Lipid Analysis Results. Ocul Surf 2016; 14: 49–55.
- Baudouin C, Messmer EM, Aragona P et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 2016; 100: 300–306.
- Goto E, Monden Y, Takano Y et al. Treatment of non‐inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol 2002; 86: 1403–1407.
- Ong BL, Larke JR. Meibomian gland dysfunction: some clinical, biochemical and physical observations. Ophthalmic Physiol Opt 1990; 10: 144–148.
- Blackie CA, Solomon JD, Greiner JV et al. Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci 2008; 85: 675–683.
- Gao YY, Di pascuale MA, Li W et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol 2005; 89: 1468–1473.